Previous 10 | Next 10 |
Castle Biosciences press release ( NASDAQ: CSTL ): Q2 GAAP EPS of -$0.06 beats by $0.70 . Revenue of $34.8M (+52.9% Y/Y) beats by $6.43M . Shares +2.7% AH. For further details see: Castle Biosciences GAAP EPS of -$0.06 beats by $0.70, revenue of $...
Q2 2022 revenue increased 53% over Q2 2021 to $34.8 million Delivered 11,034 total test reports in Q2 2022, an increase of 57% compared to Q2 2021 Skin cancer gene expression profile test report volume increased 44% compared to Q2 2021 Raising 2022 Revenue Guidance t...
Castle Biosciences ( NASDAQ: CSTL ) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.80 (-128.6% Y/Y) and the consensus Revenue Estimate is $28.37M (+24.6% Y/Y). Over the last 3 months, EPS estima...
TissueCypher® is a risk-stratification test that improves risk-appropriate clinical decision-making for patients diagnosed with non-dysplastic, indefinite or low-grade dysplasia Barrett’s esophagus Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving heal...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2022, after the close of market on Monday, Aug. 8, 2022. ...
Castle Biosciences surpasses 100,000 orders for its flagship risk-stratification test designed to help guide risk-appropriate treatment decisions for patients diagnosed with cutaneous melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innova...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced an upcoming presentation on DecisionDx®-Melanoma, the Company’s risk stratification gene expression profile (GEP) test, at the 2022 American ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been named an Arizona Top Workplace of 2022 by AZCentral , the digital home of The Arizona Republic newspaper . “E...
Data shows patients surveyed had low decision regret 1 after testing with DecisionDx ® -UM, regardless of whether their uveal melanoma tumor was at high or low risk of metastasis Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovat...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...